“Important progress in public health”
Wegovy weight loss injection: USA also approves approval for cardiovascular risk patients
Similar to insulin, medications such as “Wegovy” are also injected. The weight loss products are suitable for people suffering from obesity or diabetes.
© Getty Images
The USA has approved the weight loss injection Wegovy as a means of reducing the risk of heart attacks and other cardiovascular diseases. Patients in the USA can hope for a decisive advantage as a result.
FDA representative John Sharretts said this patient population has a higher risk of serious cardiovascular complications. “Providing a treatment option that has been proven to reduce cardiovascular risk is an important advance in public health.”
Wegovy: Health insurance companies are likely to cover more costs in the USA
Patients in the USA can now hope for a decisive advantage: the additional FDA approval should significantly increase the number of people for whom health insurance covers the costs of Wegovy. Many insurance companies will not cover the cost of a drug that is only approved for weight loss. With the new approval, there are new requirements for health insurance in the USA. My colleague Nicole Heißmann wrote down here what the current situation is in Germany.
Novo Nordisk initially caused a sensation with the diabetes drug Ozempic, which became very popular as a weight-loss injection. Later, the Danish pharmaceutical giant launched Wegovy, which contains the same active ingredient as Ozempic in a different dosage and was specifically approved by US authorities to treat obesity.
Read here even more about the weight loss injection in the big stern cover story from November 2023.